Skip to content

Study · Not a test of the peptide alone · 2017

5 results

Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting.

Hunt B, Vega-Hernandez G, Valentine WJ, Kragh N

Diabetes, obesity & metabolism23 Feb 2017Cited by 17 (Europe PMC)

PMID28124820 (opens in a new tab)DOI10.1111/dom.12890 (opens in a new tab)PepBankPUB-28124820
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a model of UK adults with type 2 diabetes, liraglutide 1.8 mg gave higher discounted quality-adjusted life expectancy than lixisenatide 20 µg.

    In plain wordsIn a computer model of type 2 diabetes care in the UK, liraglutide 1.8 mg gave more healthy life years than lixisenatide.

    Peptide
    Liraglutide
    Outcome
    IncreaseQuality-adjusted life expectancy
    Study

    n: not reported in source

    IMS CORE Diabetes Model
    Comparator
    Lixisenatide 20 µg
    Outcome group
    Cost-effectiveness · Whole body

    Measurements

    QALYs
    8.87 QALY
    liraglutide 1.8 mg
    QALYs
    8.76 QALY
    lixisenatide 20 µg

    Source sentences

    Summary
    Liraglutide 1.8 mg was associated with improved discounted quality-adjusted life expectancy (8.87 vs 8.76 quality-adjusted life years [QALYs]) vs lixisenatide 20 µg.
    2 context sentences
    Summary · context
    Projections of costs (in 2015 pounds sterling [£]) and clinical outcomes were made over patient lifetimes using the IMS CORE Diabetes Model (IMS Health, Basel, Switzerland).
    Summary · context
    The baseline cohort and treatment effects applied after initiation of GLP-1 receptor agonists were taken from the LIRA-LIXI trial.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a model of UK adults with type 2 diabetes, a greater reduction in glycated haemoglobin with liraglutide 1.8 mg led to fewer diabetes-related complications and delayed their onset.

    In plain wordsIn a computer model, liraglutide 1.8 mg led to fewer and later diabetes complications than lixisenatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseDiabetes-related complications
    Study

    n: not reported in source

    IMS CORE Diabetes Model
    Comparator
    Lixisenatide 20 µg
    Outcome group
    Diabetes complications · Whole body

    Source sentences

    Summary
    A greater reduction in glycated haemoglobin with liraglutide 1.8 mg led to fewer diabetes-related complications and delayed their time of onset.
    2 context sentences
    Summary · context
    Projections of costs (in 2015 pounds sterling [£]) and clinical outcomes were made over patient lifetimes using the IMS CORE Diabetes Model (IMS Health, Basel, Switzerland).
    Summary · context
    The baseline cohort and treatment effects applied after initiation of GLP-1 receptor agonists were taken from the LIRA-LIXI trial.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a model of UK adults with type 2 diabetes, liraglutide 1.8 mg had higher total costs than lixisenatide 20 µg, driven by higher acquisition costs.

    In plain wordsIn a computer model, liraglutide 1.8 mg cost more overall than lixisenatide, because the drug itself costs more.

    Peptide
    Liraglutide
    Outcome
    IncreaseTotal costs
    Study

    n: not reported in source

    IMS CORE Diabetes Model
    Comparator
    Lixisenatide 20 µg
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    Liraglutide 1.8 mg was associated with increased total costs (£37 153 vs £36 174), driven by higher acquisition costs
    2 context sentences
    Summary · context
    Projections of costs (in 2015 pounds sterling [£]) and clinical outcomes were made over patient lifetimes using the IMS CORE Diabetes Model (IMS Health, Basel, Switzerland).
    Summary · context
    The baseline cohort and treatment effects applied after initiation of GLP-1 receptor agonists were taken from the LIRA-LIXI trial.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  4. 04Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a model of UK adults with type 2 diabetes, liraglutide 1.8 mg gave savings from diabetes-related complications avoided compared with lixisenatide 20 µg.

    In plain wordsIn a computer model, liraglutide 1.8 mg saved some costs of diabetes complications compared with lixisenatide.

    Peptide
    Liraglutide
    Outcome
    DecreaseCosts of diabetes-related complications
    Study

    n: not reported in source

    IMS CORE Diabetes Model
    Comparator
    Lixisenatide 20 µg
    Outcome group
    Cost-effectiveness · Whole body

    Source sentences

    Summary
    but this was partially offset by savings from diabetes-related complications avoided (£26 969 vs £27 912).
    2 context sentences
    Summary · context
    Projections of costs (in 2015 pounds sterling [£]) and clinical outcomes were made over patient lifetimes using the IMS CORE Diabetes Model (IMS Health, Basel, Switzerland).
    Summary · context
    The baseline cohort and treatment effects applied after initiation of GLP-1 receptor agonists were taken from the LIRA-LIXI trial.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  5. 05Computer modelNot a test of Liraglutide aloneIn silicoOther

    In a model of UK adults with type 2 diabetes, liraglutide 1.8 mg had an incremental cost-effectiveness ratio of £8901 per QALY gained versus lixisenatide 20 µg.

    In plain wordsIn a computer model, liraglutide 1.8 mg cost £8901 for each healthy life year gained compared with lixisenatide.

    Peptide
    Liraglutide
    Outcome
    Not applicableIncremental cost-effectiveness ratio
    Study

    n: not reported in source

    IMS CORE Diabetes Model
    Comparator
    Lixisenatide 20 µg
    Outcome group
    Cost-effectiveness · Whole body

    Measurements

    ICER
    8901 £ per QALY
    vs lixisenatide 20 µg

    Source sentences

    Summary
    Liraglutide 1.8 mg was associated with an incremental cost-effectiveness ratio of £8901 per QALY gained vs lixisenatide 20 µg.
    2 context sentences
    Summary · context
    Projections of costs (in 2015 pounds sterling [£]) and clinical outcomes were made over patient lifetimes using the IMS CORE Diabetes Model (IMS Health, Basel, Switzerland).
    Summary · context
    The baseline cohort and treatment effects applied after initiation of GLP-1 receptor agonists were taken from the LIRA-LIXI trial.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01973231

Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 404Oct 2013 to Nov 2014

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 9 Feb 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 16:36 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    12 Oct 2026, 12:10 UTC

    Study results updated

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.